Drogsan Pharmaceuticals, one of the leading pharmaceutical companies of Turkey, signed a strategic collaboration agreement with Rockwell Medical for offering their FDA-approved innovative iron deficiency anemia drug in the Turkish market.
In 2014, Drogsan, offering the first domestic biosimilar drug to the market in Turkey and specializing in nephrology, joined its forces with Rockwell, a company that is committed to treating iron deficiency and transforming the anemia method. Through this collaboration, Drogsan will be able to market the innovative drug developed by Rockwell for the treatment of iron deficiency anemia of patients who take hemodialysis in Turkey and surrounding countries.
Drogsan Chairman and CEO Mustafa Karpuzcu said, "We welcome this opportunity to cooperate with Rockwell Medical and offer this innovative treatment for the hemodialysis patients in Turkey. There are approximately 65.000 hemodialysis patients in Turkey, a number that is increasing every day. We believe that this partnership has vital importance in meeting the effective and safe innovative treatment need of iron deficiency anemia patients."
Rockwell Medical Chairman and CEO Dr. Russel Ellison said, "While we continue to increase the number of opportunities for patients all around the world to access our innovative hemodialysis product, this represents an important improvement for meeting the needs of patients with iron deficiency in Turkey. Drogsan has a strong past in this field with its 45 years of pharmaceutical experience, corporate infrastructure, successful new product launches and quite experienced nephrology team. Therefore, we look forward to working closing with Drogsan, our partner, to offer our innovative product to the patients in need."
About Drogsan Pharmaceuticals
Drogsan Pharmaceuticals, established in 1975 as an affiliate of Nevzat Group and still operating in the health industry with its 1.400 employees and a total of USD 400 million in turnover is one of the leading pharmaceutical companies of Turkey. Drogsan entered the field of nephrology by launching the first domestically produced biosimilar product of Turkey in 2014 and aims to become the leader in this field. With its strong manufacturing capacity and international collaborations, Drogsan meets the needs of Turkey in select therapeutic fields while also providing services through exports to more than 30 countries in East and South Europe, Commonwealth of Independent States, Middle East, Africa, Central and Southeast Asia.
About Rockwell Medical
With its new generation parenteral iron technology platform, Rockwell Medical is a biopharmaceutical company that develops and commercializes innovative products that have the potential to decrease the healthcare costs and increase the quality of life for patients, to transform the iron deficiency treatment that arises in different disease conditions. The first two products developed by Rockwell in this treatment platform were certified by FDA for the iron deficiency treatment of hemodialysis patients. In this platform, Rockwell Medical continues to develop products also for patients taking dialysis treatment at home. In addition, Rockwell Medical is one of the two largest suppliers that provide hemodialysis concentrates to the dialysis clinics in the United States of America.